Immunotherapy plus chemoradiation for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiation works better than chemoradiation alone for people with a specific type of advanced nasopharyngeal cancer. It aims to shrink tumors before surgery and prevent cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed type of nasopharyngeal cancer called non-keratinizing
- You are 18 years or older
- Your cancer has spread to lymph nodes in the neck (N3 stage) but not to other parts of the body
- You are in good physical condition (able to do daily activities without help)
- Your blood counts and liver and kidney function are within acceptable ranges
- You do not have active hepatitis B, hepatitis C, HIV, or an autoimmune disease like lupus or rheumatoid arthritis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests whether giving an immunotherapy drug (sintilimab) combined with a pill chemotherapy (capecitabine) after standard treatment can help prevent nasopharyngeal cancer from coming back in people with high-risk stages. You must have already completed standard chemo-immunotherapy and radiation.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests two drugs—scipibaimab and tislelizumab—given together for people with nasopharyngeal cancer that has not responded to first-line platinum chemotherapy and a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.